A phase II study of Ampligen (rintatolimod) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2016
At a glance
- Drugs Rintatolimod (Primary)
- Indications Chronic fatigue syndrome; Encephalomyelitis
- Focus Therapeutic Use
- 23 Aug 2016 According to a Hemispherx Biopharma media release, based on the date from this and other studies the Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica (ANMAT) approved Rintatolimod in the Argentine Republic for the treatment of severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
- 17 Mar 2016 New trial record